Empreendimentos Pague Menos S.A. (BVMF:PGMN3)

Brazil · Delayed Price · Currency is BRL

3.600

-0.110 (-2.96%)

At close: Jul 8, 2026

8.43% (1Y)

Market Cap	2.59B +23.8%
Revenue (ttm)	15.34B +16.9%
Net Income	307.53M +112.2%
EPS	0.48 +103.7%
Shares Out	719.24M
PE Ratio	7.54
Forward PE	6.32
Dividend	0.26 (7.16%)
Ex-Dividend Date	Dec 26, 2025

Volume	4,919,600
Open	3.690
Previous Close	3.710
Day's Range	3.600 - 3.710
52-Week Range	3.240 - 7.620
Beta	-0.04
Analysts	Buy
Price Target	7.83 (+117.5%)
Earnings Date	Aug 3, 2026

About BVMF:PGMN3

Empreendimentos Pague Menos S.A. engages in the retail sale of medicines, perfumeries, and personal hygiene and beauty products in Brazil. The company offers medicines and health care products; personal hygiene products, including deodorant, intimate care, and oral hygiene; foot, hair, face, and hand care products; dermo and beauty products; and repellent, diaper, cloth, and food products, as well as other accessories for moms and babies. The company also offers vaccines, clinical analysis tests, and basic health services; clothing and accessor... [Read more]

Industry Pharmaceutical Retailers

Sector Healthcare

Founded 1981

Employees 28,316

Stock Exchange Brazil Stock Exchange

Ticker Symbol PGMN3

Full Company Profile

Financial Performance

In 2025, BVMF:PGMN3's revenue was 14.91 billion, an increase of 17.91% compared to the previous year's 12.64 billion. Earnings were 260.28 million, an increase of 152.46%.

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for PGMN3 stock is "Buy." The 12-month stock price target is R$7.83, which is an increase of 117.50% from the latest price.

Price Target

R$7.83

(117.50% upside)

Analyst Consensus: Buy

Stock Forecasts

News

Empreendimentos Pague Menos Earnings Call Transcript: Q1 2026

Q1 2026 saw 14.4% revenue growth, 36% EBITDA growth, and net income quadrupling year-over-year, with strong market share gains in the North and Northeast and a focus on continuous care customers. Margin expansion, disciplined capital allocation, and digital growth underpin a positive outlook.

2 months ago - Transcripts

Empreendimentos Pague Menos Earnings release: Q1 2026

Empreendimentos Pague Menos released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.

2 months ago - Filings

Empreendimentos Pague Menos Slides: Q1 2026

Empreendimentos Pague Menos has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.

2 months ago - Filings

Empreendimentos Pague Menos Earnings Call Transcript: Q4 2025

Achieved record revenue and EBITDA growth in 2025, driven by strong same-store sales, digital expansion, and operational efficiency. Market share and profitability improved, with disciplined capital allocation and a focus on scaling logistics and generics in 2026.

4 months ago - Transcripts

Empreendimentos Pague Menos Earnings release: Q4 2025

Empreendimentos Pague Menos released its Q4 2025 earnings on March 2, 2026, summarizing the period's financial results.

4 months ago - Filings

Empreendimentos Pague Menos Slides: Q4 2025

Empreendimentos Pague Menos has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 2, 2026.

4 months ago - Filings

Empreendimentos Pague Menos Earnings Call Transcript: Q3 2025

Revenue grew 18% year-over-year, with same-store sales up 17.6% and EBITDA rising 36.4%. Prescription and generic drugs drove growth, while net income increased 50%. Market share, customer base, and store productivity all improved, with further gains expected.

8 months ago - Transcripts